{"id":16997,"date":"2023-08-14T12:30:00","date_gmt":"2023-08-14T11:30:00","guid":{"rendered":"https:\/\/vascular.hu\/holding\/?p=16997"},"modified":"2024-02-09T12:36:21","modified_gmt":"2024-02-09T11:36:21","slug":"vrg-therapeutics-demonstrates-in-vivo-efficacy-with-a-selective-kv1-3-inhibitor-developed-for-autoimmune-diseases-2","status":"publish","type":"post","link":"https:\/\/vascular.hu\/holding\/vrg-therapeutics-demonstrates-in-vivo-efficacy-with-a-selective-kv1-3-inhibitor-developed-for-autoimmune-diseases-2\/","title":{"rendered":"VRG Therapeutics has secured \u20ac5 Million in Series A Funding"},"content":{"rendered":"\n\nPress release\n<\/a>\n\n\n\n

\nBUDAPEST, HUNGARY, August 14, 2023\/\nEINPresswire.com<\/a>\/ — \nVRG Therapeutics<\/a>(VRG Tx), a pioneering biotechnology research and development company specializing in miniprotein-based pharmaceuticals and cellular & gene therapy (CGT) products, is pleased to announce that it has successfully secured a \u20ac5 million investment deal. The funding was led by the Budapest based Sz\u00e9chenyi Funds (SZTA) with the participation of Vascular Group, the incumbent seed investor.\n
\nVRG Tx’s breakthrough individual sequence enrichment pattern (ISEP) platform harnesses the power of directed evolution to create miniprotein-based therapeutics and CGT applications. This unique approach draws from the evolutionary conserved structures of natural peptides and employs cutting-edge next-generation sequencing (NGS) analytics to design novel therapeutic candidates. These candidates offer unparalleled selectivity and affinity, combining the advantages of both small molecules and biologics.\n
\nThe investment, led by Sz\u00e9chenyi Funds, underscores its commitment to innovation. As part of the investment, Sz\u00e9chenyi Funds will appoint members to VRG Tx’s new Board. This strategic collaboration positions VRG Tx for continued growth and development. The funding enables VRG Tx to progress its pre-clinical drug candidate portfolio to IND enabling studies in indications with major unmet clinical needs including migraine prophylaxis, central nervous system (CNS) disorders, autoimmune diseases and glioblastoma multiforme (GBM). Securing this investment provides a strong basis for VRG Tx\u2019s ongoing Series A fundraising efforts to advance its diverse portfolio of projects.\n
\n\nAbout VRG Tx<\/a>: VRG Therapeutics is an innovative biopharmaceutical R&D company headquartered in Budapest, Hungary. VRG Tx is committed to leveraging its proprietary miniprotein ISEP technology to tackle diseases through mechanisms that conventional biopharmaceutical approaches cannot achieve.\n
\n\nAbout Sz\u00e9chenyi Funds (SZTA)<\/a>: Sz\u00e9chenyi Funds is a major Hungarian venture capital and private equity investor focusing on companies with robust growth potential related to Hungary and the CEE region. They manage \u20ac 400 million in assets and 80+ portfolio companies in a well-balanced portfolio representing several industries.\n
\nZalan Peterfi\n
\nVRG Therapeutics\n
\n\nemail us here\n<\/a>\n
\nVisit us on social media:\n
\n\nLinkedIn\n<\/a>\n<\/p>\n","protected":false},"excerpt":{"rendered":"

Press release BUDAPEST, HUNGARY, August 14, 2023\/ EINPresswire.com\/ — VRG Therapeutics(VRG Tx), a pioneering biotechnology research and development company specializing in miniprotein-based pharmaceuticals and cellular & gene therapy (CGT) products, is pleased to announce that it has successfully secured a \u20ac5 million investment deal. The funding was led by the Budapest based Sz\u00e9chenyi Funds (SZTA) […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[81,42],"tags":[],"class_list":["post-16997","post","type-post","status-publish","format-standard","hentry","category-news","category-vascular-reserach-group"],"_links":{"self":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts\/16997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/comments?post=16997"}],"version-history":[{"count":5,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts\/16997\/revisions"}],"predecessor-version":[{"id":17002,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts\/16997\/revisions\/17002"}],"wp:attachment":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/media?parent=16997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/categories?post=16997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/tags?post=16997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}